Skip to main content

Table 6 Suggested frequency of echocardiography surveillance during and after pregnancy [27, 39, 40]

From: Transthoracic Echocardiographic Assessment of the Heart in Pregnancy—a position statement on behalf of the British Society of Echocardiography and the United Kingdom Maternal Cardiology Society

Condition

During pregnancy

Post-partum

Level of evidence and strength of recommendation

Valvular disordersa

As early as possible if not performed pre-pregnancy

  

Stenotic lesions

Mild AS:

  
 

 Once mid gestation only

3–5 years

IIaC

 

Mild MS:

  
 

 Once 2nd and 3rd trimester

3–5 years

IIaC

 

Moderate AS:

  
 

 Once 2nd and 3rd trimester and prior to delivery

12 months

IIaC

 

Severe AS:

  
 

 4–8 weekly depending on symptoms, and prior to delivery

Pre-discharge, then 3 months

IC

 

Moderate and severe MS:

  
 

 4–8 weekly depending on symptoms, and prior to delivery

Pre-discharge, then 3 months

IC

Regurgitant lesions

Mild AR/MR, moderate PR/TR:

  
 

 Once mid gestation

As per usual follow-up

IIaC

 

Moderate AR/MR, severe PR/TR: 

  
 

 Once 2nd and 3rd trimester

6 months

IIaC

Tissue prostheses

Severe: S Severe AR/MR:

  
 

 8 weekly depending on symptoms

Pre-discharge, then 6 months

IIaC

Mechanical prostheses

As for native valve disease

Pre-discharge, then 1–2 months

IC

 

4 weekly if functionally normal

 

IC

Cardiomyopathy

   

 Dilated cardiomyopathy

4–8 weekly, increasing to 1–4 weekly, if LVEF <40%

Pre-discharge, then 4–8 weeks, depending on ventricular function/recovery

IC

 Hypertrophic cardiomyopathy

If symptomatic, systolic dysfunction, impaired diastolic function with raised filling pressure or obstruction, 4 weekly, otherwise once only

Pre-discharge, then 4-8 weeks if complicated or obstruction, otherwise 3–6 months

IIaC

 ARVC

4–8 weekly, depending on RV function

Pre-discharge, then 4 weeks, if impaired RV function, otherwise 3–6 months

IIaC

 Previous peripartum cardiomyopathy , with recovered LV function

End first trimester and end second trimester

Prior to discharge and one month after delivery

IC

 Inherited aortopathies

4–12 weekly, depending on clinical scenario, as determined by the pregnancy heart teamb

Pre-discharge, then 4–12 weeks, depending on clinical scenario

IC

Congenital heart diseasec

   

 ASD with right heart dilatation, unrepaired

Once, not required if small

As per usual follow-up

IIaC

 Fallot

If impaired RV  function 4–8 weekly, otherwise once

Pre-discharge and 4–8 weeks if impaired RV function, otherwise 3–6 months

IIaC

 TGA with systemic right ventricle

4–8 weekly, depending on clinical scenario

Pre-discharge, then 4–8 weeks

IIaC

 Fontan

8 weekly, depending on clinical scenario/once

Pre-discharge only impaired ventricular function, otherwise 3–6 months

IIaC

Coronary artery disease

Once only, if no residual ventricular dysfunction

As per usual follow up

IIC

Hypertensive disorders of pregnancy

Only if suspicion of heart failure, or coarctation of the aorta

Not usually indicated

IC

Pulmonary arterial hypertension

4 weekly, increasing to 2–4 weekly, depending on RV function, as determined by the pregnancy heart team

Prior to discharge and at 4–8 weeks

IC

  1. ARVC arrhythmogenic right ventricular cardiomyopathy, AR aortic regurgitation, AS aortic stenosis, ASD atrial septal defect, EF ejection fraction, LV left ventricular, MR mitral regurgitation, MS mitral stenosis, PR pulmonary regurgitation, RV right ventricular, TGA transposition of the great arteries, TR tricuspid regurgitation
  2. aDegree of valve stenosis/regurgitation is based on pre-pregnancy scan. Post-partum follow up of mild and moderate valve disease can, in general, be as per BSE guidelines. In more severe disease, the pregnancy or simply the passage of time may have progressed the disease and earlier follow up is advised
  3. bFrequency depends on the risk of dilatation, which is related to the aortic diameter, the underlying condition and the family history of dissection
  4. cDictated by ventricular function and valve disease